(19)
(11) EP 4 408 867 A2

(12)

(88) Date of publication A3:
28.09.2023

(43) Date of publication:
07.08.2024 Bulletin 2024/32

(21) Application number: 22926917.0

(22) Date of filing: 27.09.2022
(51) International Patent Classification (IPC): 
C07K 14/47(2006.01)
A61K 48/00(2006.01)
 A61K 38/17(2006.01)
A61P 25/28(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/1709
(86) International application number:
PCT/IB2022/000623
(87) International publication number:
WO 2023/156807 (24.08.2023 Gazette 2023/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 27.09.2021 US 202163248555 P
27.09.2021 US 202163249022 P

(71) Applicant: Curelab Oncology, Inc.
Dedham, MA 02026-6612 (US)

(72) Inventors:
  • SHNEIDER, Alexander
    Dedham, MA 02026-6612 (US)
  • AGAS, Dimitrios
    62032 Camerino (IT)
  • GABAI, Vladimir
    Brighton, MA 02135-7776 (US)
  • SUFIANOV, Albert A.
    Tyumen 625032 (RU)
  • SABBIETI, Maria Giovanna
    62032 Camerino (IT)

(74) Representative: Benatov, Samuil Gabriel 
Dr. EMIL BENATOV & PARTNERS 6, Asen Peykov Str.
1113 Sofia
1113 Sofia (BG)

   


(54) PREVENTION AND TREATMENT OF DISEASES BY MODULATING ACTIVITY OF MESENCHYMAL STEM CELLS WITH P62 (SQSTM1)-ENCODING VECTOR AND PHARMACEUTICAL FORMULATIONS CONTAINING P62 (SQSTM1) PROTEINS